RSV vaccines

Acceptability of RSV maternal vaccine is dependent on increasing the awareness of RSV. 

Stakeholder acceptability will depend on increased awareness of the pathogen, the diseases it causes and the potential benefit of the vaccine against diseases that they recognize. However, the cost of RSV vaccination is likely to influence how national immunization programmes will prioritize its introduction relative to other vaccines and public health interventions.^{Go to footnote 11}

A systematic review of 61 studies found that knowledge and awareness of RSV prevention are generally low, but attitudes toward vaccines and other preventive options are mostly positive across target populations. Acceptance is driven by perceived disease severity and protection benefits, while safety concerns act as key barriers, with maternal vaccination generally viewed more favourably than infant immunization.^{Go to footnote 22}

In the Gambia, willingness to receive maternal RSV vaccination during pregnancy or lactation was high despite low awareness of RSV. Safety concerns and limited awareness were the main barriers to vaccine acceptance.^{Go to footnote 33}

Both maternal and infant RSV immunization strategies were generally seen as acceptable and feasible in Kenya, Nepal, and Peru when integrated into existing health systems. However, successful introduction will depend on country-specific factors such as community acceptance, health system capacity, availability of epidemiological data, and affordability.^{Go to footnote 44}

For mAbs, acceptability to key stakeholders will depend on whether the price of the product is affordable in the country. Wide use of mAbs for passive immunization has never been implemented in LMICs.^{Go to footnote 55, Go to footnote 66}